Published by Iain Gilbert on 4th August 2022
(Sharecast News) - Drugmaker AstraZeneca's Lynparza has received European Union approval for use in the adjuvant treatment of adult patients with high-risk early-stage breast cancer, including those with germline BRCA mutations.
URL: http://www.digitallook.com/dl/news/story/32869494/...